WATERTOWN, Mass., Nov. 5, 2010 /PRNewswire/ -- EnVivo Pharmaceuticals today announced it has discovered that EVP-6124, its alpha-7 nicotinic acetylcholine receptor agonist, possesses a novel mechanism not previously seen in the scientific community: it acts as a co-agonist with Acetylcholine (ACh) to enhance cognition.
By acting as a co-agonist and sensitizing the alpha-7 receptor, EVP-6124 makes it possible for smaller amounts of naturally occurring ACh, typically found in individuals with memory disorders such as Alzheimer’s, to be required to activate the receptor. In this scenario, EnVivo’s research demonstrated that memory deficits can be minimized or entirely reversed by controlling the neuronal channel with EVP-6124 alone or in combination with other Alzheimer’s drugs.
“This is groundbreaking research in terms of understanding how the alpha-7 receptor operates in conjunction with EVP-6124,” said Kees Been, president and CEO of EnVivo. “The potential, as evidenced in our studies, is significant for how we look at and approach the treatment of Alzheimer’s disease.”
EnVivo simulated physiologically relevant brain conditions in vitro and alpha-7 receptor action was measured in response to ACh in the presence of low EVP-6124 concentrations. At drug concentrations resulting in pro-cognitive effects in in vivo studies, EVP-6124 appeared to significantly increase the alpha-7 receptor response to ACh. This suggests that at low concentrations, EVP-6124 acts as a co-agonist and sensitizes the alpha-7 receptor to its natural response to ACh, but does not desensitize the receptor. This co-agonist mechanism of action was supported by testing the combined effect of sub-threshold doses of both EVP-6124 and donepezil (Aricept) on the memory deficit in a rat model. While each drug alone at these very low doses had no effect on reversing the deficit, dosing the two agents together completely restored the memory function in these animals.
“Low doses of EVP-6124 could enhance current cholinergic treatments and when combined with available agents could provide a pro-cognitive effect for as long as acetylcholine is present in the brain,” said Dr. Jeff Cummings, director of the Cleveland Clinic Lou Ruvo Center for Brain Health (Las Vegas, Nevada and Cleveland, Ohio). “EnVivo’s experimental results suggest that pro-cognitive drugs could be taken in earlier stages of Alzheimer’s disease and that EVP-6124 could continue to boost the pro-cognitive effect of cholinesterase inhibitors throughout the disease course. The effectiveness of reduced doses of cholinesterase inhibitors when given with EVP-6124 in experimental models suggests that EVP-6124 might allow use of lower doses with fewer side effects in humans.”
The results of EnVivo’s ongoing Phase IIb trial, expected in the second half of 2011, will hopefully further corroborate EnVivo’s most recent findings.
About EnVivo Pharmaceuticals
EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer’s disease, cognitive disorders and schizophrenia. The company’s lead product is an alpha-7 nicotinic acetylcholine receptor agonist and is currently in Phase IIb clinical trials for cognition disorders in Alzheimer’s disease and schizophrenia. The company’s other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule which is in preparation for Phase II studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer’s disease) and a PDE10 inhibitor program (for schizophrenia), expected to enter the clinic in 2011. For more information aboutEnVivo, visitwww.envivopharma.com.
SOURCE EnVivo Pharmaceuticals
